Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 10 2021 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 7, 2021
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S purchases
B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme
Bagsværd,
Denmark, 7 May 2021 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK
0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2021 share repurchase
programme of up to a total of DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. The transaction
price is DKK 461.04 per share and has been calculated as the three-day volume weighted average market price from 5 May 2021 to
7 May 2021 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results.
Prior to the sale of B shares, Novo Holdings
A/S’ ownership of Novo Nordisk A/S was 28.5% of the share capital and 76.9% of the votes. Following the transaction, Novo
Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 116,129,000 B shares of DKK 0.20, corresponding to 28.3% of the capital
and 76.8% of the votes in Novo Nordisk A/S.
The transaction is in line with the announcement
on 5 May 2021 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share capital around 28%.
In addition, transactions related to Novo Nordisk’s
incentive programmes have resulted in a net transfer from Novo Nordisk of 9,954 B shares in the period from 5 May 2021 to 7 May
2021.
With the transactions
stated above, Novo Nordisk A/S owns a total of 11,257,435 B shares of DKK 0.20, corresponding to 0.5% of the share capital, as
treasury shares. The total amount of A and B shares in the company is 2,310,000,000 of DKK 0.20 including treasury shares.
Page 2 of 2
About Novo Holdings A/S
Novo
Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of
the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk
Foundation’s assets. Novo Holdings is recognized as a leading international life science investor, with a focus on
creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage
companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a
broad portfolio of diversified financial assets. Further information: www.novoholdings.dk.
About Novo Nordisk A/S
Novo Nordisk
is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about
45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen
(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter,
LinkedIn, YouTube.
Further information
Media:
|
|
mkd@novonordisk.com
|
Mette Kruse Danielsen
|
+45 3079 3883
|
Michael Bachner (US)
|
+1 609 664 7308
|
mzyb@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
David Heiberg Landsted
|
+45 3077 6915
|
dhel@novonordisk.com
|
Mark Joseph Root (US)
|
+1 848 213 3219
|
mjhr@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 31 / 2021
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 7, 2021
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Aug 2023 to Aug 2024